(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Top 10 Books That Will Have an impact on Your Viewpoint - 2The new queen of country music has no scandals and no gimmicks — and just broke a record set by Taylor Swift
- 3The Reduced Portage Horse: An Inheritance Reconsidered for Present day Experience
- 4These men carry towers of birds through Mexico's streets. They say their tradition is dying out.
- 5Kennedy approves adding two rare disorders to newborn screenings
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- Italy Brings In New Measures In 2026 To Tackle Overtourism
- Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
- Cuba fights to contain spread of mosquito-borne chikungunya virus
- Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- Verdicts against social media companies carry consequences. But questions linger
- Photos of amputees in Gaza, struggling to survive after losing limbs to Israeli airstrikes
